Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy

Conclusions: A ceftolozane/tazobactam dose of 500 mg/250 mg appears to be sufficient to attain pharmacokinetic/pharmacodynamic targets during PIRRT while the manufacturer ’s recommended dosing of 100 mg/50 mg every 8 h was sufficient during non-PIRRT periods.Chemotherapy 2018;63:203 –206
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research